ZOMDFOTCPharmaceutical PreparationsFiscal year ends December 31
Zomedica Corp.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$0.08−0.00 (-0.55%)
Close on Oct 19, 2026
- Market cap
- $77.40M
- P/E (TTM)
- –
- Dividend yield
- –
Zomedica Corp. revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Therapeutic Devices | $26.20M | $24.85M | $23.81M | $18.54M | $4.01M | – | – | – | – | – | 81.8% | +5.4% |
| Development Services | $3.03M | – | – | – | – | – | – | – | – | – | 9.5% | – |
| Diagnostics | $2.80M | $2.43M | $1.38M | $391.00K | $125.00K | – | – | – | – | – | 8.7% | +15.1% |
| Total [Member] | – | – | – | – | $4.13M | – | – | – | – | – | – | – |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Consumables | $20.68M | $17.66M | $16.31M | $11.46M | – | – | – | – | – | – | 64.6% | +17.1% |
| Capital | $9.25M | $9.49M | $8.79M | $7.34M | – | – | – | – | – | – | 28.9% | -2.5% |
| Engineering | $1.98M | – | – | – | – | – | – | – | – | – | 6.2% | – |
| Other | $123.00K | $131.00K | $85.00K | $136.00K | – | – | – | – | – | – | 0.4% | -6.1% |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $26.46M | $22.56M | $20.68M | – | – | – | – | – | – | – | 82.6% | +17.3% |
| Foreign countries | $5.57M | $4.73M | $4.50M | – | – | – | – | – | – | – | 17.4% | +17.8% |
From the segment and revenue-disaggregation notes of Zomedica's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.